Possible Promise
Make Your Future Promise Possible
Source: PR Newswire
DUBLIN, Feb. 24, 2021 /PRNewswire/ — The “Global Hepatitis B Virus (HBV) Market: 10 Year Demand Forecast & Impact of COVID-19 (2021-2030)” report has been added to ResearchAndMarkets.com’s offering. The global hepatitis B virus (HBV) market is expected to reach US$35.63 billion in 2030,…
Source: Business Wire
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided operational highlights. “With $735 million in cash at the end of the year, plus $220 million from Gilead’s recent equity investment, we are extremely well-positioned to accelerate the advancement of our pipeline, initiate our firs
Source: OpenPR
In the recent past, cancer therapy such as targeted immunotherapies that includes CAR-T cell therapies is been preferred over surgery, chemotherapy, and radiation. These target cancer cells and strengthen the patient’s immune system against the tumor. CAR-T cell therapy is
Source: MarketScreener
Europe’s drugs regulator said on Tuesday it is evaluating the use of remdesivir in COVID-19 patients who do not need oxygen support, after developer Gilead Sciences submitted an application to extend… | February 23, 2021
Source: Business Wire
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:40 p.m. EST Cowen Annual Health Care Conference on Thursday, March 4, 2021 at 12:10 p.m. EST The live webcasts can be accessed at the company’s investors page at investors.gilead.com. The replays will be available for at least 14 days following the presen
Source: Invezz
Gilead Sciences says Veklury sales made up 25% of the total Q4 revenue. Gilead forecasts up to £18.34 billion of total product sales in fiscal 2021.
Source: Business Wire
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new partnership with the Wake Forest University School of Divinity, one of the leading academic and faith-based institutions in the United States, as part of the company’s ongoing COMPASS Initiative®. Through COMPASS, Gilead works with non-profit and academic institutions, which serve as coordinating centers that direct support to local community organizations through grants, training and collaborative
Source: OpenPR
Global gene therapy market is poised for robust growth with net revenue pool set to exceed approximately US$ 5 Bn by 2026 end. The market is receiving tailwinds from advancements in synthetic biology. On that premise, the gene therapy market
Source: WRAL TechWire
As Monday morning rolls in, we’re providing TechWire readers with a quick recap of the past week’s news headlines. Notable local news stories from last week
Source: Watchlist News
Gilead Sciences, Inc. (NASDAQ:GILD) EVP Brett A. Pletcher sold 1,975 shares of the stock in a transaction on Wednesday, February 10th. The shares were sold at an average price of $67.41, for a total value of $133,134.75. Following the completion of the sale, the executive vice president now directly owns 28,832 shares of the company’s […]
